Jeffrey Zangmeister
Hematology & Oncology · Columbus, OHNPI 1871541979
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,488 of the $5,500 with a category attached, or 63.4%. 35 manufacturers reported payments, led by Seagen Inc. at 31.8% of the total. Reporting peaked in 2019 at $1,930 and has fallen 87.1% since, to $249 in 2024.
Across 97 payments — averaging $56.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$2K
- Incyte Corporation$554
- Daiichi Sankyo Inc.$537
- Rigel Pharmaceuticals, Inc.$343
- Beigene USA, Inc.$293
- AstraZeneca$255
- plus $2K from 29 others
What the payments were for
- Consulting fees$5009%
- Speaking & faculty fees$1,50027%
- Food & beverage$3,48863%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 5 | $1,750 |
| Incyte Corporation | 7 | $554 |
| Daiichi Sankyo Inc. | 3 | $537 |
| Rigel Pharmaceuticals, Inc. | 3 | $343 |
| Beigene USA, Inc. | 3 | $293 |
| AstraZeneca | 3 | $255 |
| Eisai Inc. | 14 | $214 |
| Jazz Pharmaceuticals Inc. | 2 | $142 |
| ADC Therapeutics America, Inc. | 2 | $129 |
| Lilly USA, LLC | 1 | $124 |
| Ipsen Biopharmaceuticals, Inc | 2 | $116 |
| Karyopharm Therapeutics Inc. | 1 | $110 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $103 |
| Coherus Oncology, Inc. | 5 | $83 |
| Genentech USA, Inc. | 1 | $82 |
| Taiho Oncology, Inc. | 6 | $79 |
| Bristol Myers Squibb | 3 | $65 |
| Agios Pharmaceuticals, Inc. | 2 | $64 |
| Sanofi | 4 | $60 |
| AMAG Pharmaceuticals, Inc. | 3 | $54 |
| EMD Serono, Inc. | 3 | $40 |
| Exelixis Inc. | 2 | $39 |
| GSK | 2 | $36 |
| Acceleron Pharma, Inc. | 2 | $33 |
| Amgen | 2 | $31 |
| Foundation Medicine, Inc. | 2 | $27 |
| AbbVie | 1 | $21 |
| Merck | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $15 |
| Secura Bio, Inc. | 1 | $15 |
| Dova Pharmaceuticals | 1 | $13 |
| Gilead | 1 | $12 |
| Heron Therapeutics, Inc. | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,500 in reported general payments places this provider in the 60th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Columbus
- Taral PatelColumbus$888K
- Tarek ChidiacColumbus$765K
- Sameh MikhailColumbus$135K
- Erin BertinoColumbus$73K
- Mark KnappColumbus$67K
- Kathleen KerriganColumbus$47K
- Hillard LazarusCleveland$2M
- Kasra KaramlouSandusky$1.8M
- David WaterhouseCincinnati$1.3M
- Saulius GirniusMontgomery$707K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.